Identification

Generic Name
Topsalysin
DrugBank Accession Number
DB05160
Background

Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.

Type
Small Molecule
Groups
Investigational
Synonyms
  • Topsalysin
External IDs
  • PRX-302
  • PRX302

Pharmacology

Indication

Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 destroys the cells by punching holes in the cell membrane.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
LSA9D0A43Q
CAS number
917121-25-6

References

General References
Not Available
PubChem Substance
347909989

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentLocally Recurrent Prostate Cancer1
2CompletedTreatmentProstate Cancer2
1CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51